Art. -Nr.: HY-N4170

Chebulic acid

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 23725-05-5
Formel: C₁₄H₁₂O₁₁
Molecular Weight:356.24

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Chebulic acid Chemical Structure

CAS. Nr.: 23725-05-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	0.62 mM Compound: 15	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.73 mM Compound: 15	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]

In Vitro

Chebulic acid (0.5, 1, 5 and 10 μg/mL; 24 h) reduces UPM-induced ROS generation in NCI-H441 at doses of 5 and 10 μg/mL^[1].
Chebulic acid (5 and 10 μM; 24 h) dose-dependently reduces the expression levels of inflammatory factors in NCIH441 and dose-dependently increases the mRNA expression levels of Occludin and ZO-1 proteins in NCI-H441 in the presence of UPM^[1].
Chebulic acid (0-250 μM; 24 h) has a mild toxic effect on HUVEC at doses above 50 μM^[3].
Chebulic acid (0, 5, 10 and 25 μM; 24 h) dose-dependently reduces glycer-AGEs-induced ROS generation in HUVECs and THP-1 monocyte adhesion, and dose-dependently promotes the restoration of TER in HUVECs at doses of 10 and 25 μM^[3].
Chebulic acid (1, 10 and 100 μg/mL; 30 min) protectes hepatocytes from the cytotoxicity of t-BHP in a dose-dependent manner^[4].
Chebulic acid (0-26 μM; 24 h) increases the expression of Nrf2 in the nucleus of L-02 cells in a dose-dependent and time-dependent manner, and increases the phosphorylation levels of ERK, JNK and p38 MARK^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

hepatocytes
Concentration:

1, 10 和 100 μg/mL
Incubation Time:

30 min
Result:

Caused LDH leakage and MDA formation in t-BHP-treated cells, and decreased intracellular ROS levels in a dose-dependent manner. Caused t-BHP-treated cells to show cell viability similar to that of the control group at a dose of 100 μg/ml.

In Vivo

Chebulic acid (37.5, 75 and 150 mg/kg; p.o.; once daily for 5 days) is non-toxic to the liver of male ICR mice, protects against CCL4-induced liver injury through Nrf2 signaling and reduces serum ALT and AST levels and liver injury levels, including reduces necrosis and histological improvement^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar albino rats of ischemia-reperfusion model^[1].
Dosage:

25, 50 mg/kg
Administration:

Oral gavage (p.o.) once a day for 28 days
Result:

Reduced blood glucose, creatinine, urea nitrogen, glycated hemoglobin, proteinuria, urinary albumin excretion, glomerular filtration rate (GFR), and increased serum insulin and glycogen levels in diabetic rats.

Chemical Information

CAS. Nr. 23725-05-5
Appearance Solid
Molecular Weight 356.24
Formel C₁₄H₁₂O₁₁
Color White to off-white
SMILES

O=C([C@@H](CC(O)=O)[C@H]([C@H](O1)C(O)=O)C2=C(C(O)=C(C=C2C1=O)O)O)O
Structure Classification
- Phenols
- Polyphenols
- Ketones, Aldehydes, Acids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

J Exp Med

Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice. [Abstract]

2021 May 3;218(5):e20202033. PMID: 33688918
J Ethnopharmacol

Protecting the brain from stroke: Huoxue Rongluo formula (HXRLF) targets ferroptosis for neuroprotection. [Abstract]

2025 Jul 29;353(Pt A):120329. PMID: 40744419

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (140.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8071 mL

14.0355 mL

28.0710 mL

5 mM

0.5614 mL

2.8071 mL

5.6142 mL

10 mM

0.2807 mL

1.4035 mL

2.8071 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.17 mg/mL (6.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee KW, et al. Protective effects of chebulic acid on alveolar epithelial damage induced by urban particulate matter. BMC Complement Altern Med. 2017 Jul 19;17(1):373. [Content Brief]

[2]. Silawat N, et al. Chebulic acid attenuates ischemia reperfusion induced biochemical alteration in diabetic rats. Pharm Biol. 2013 Jan;51(1):23-9. [Content Brief]

[3]. Lee H S, et al. Preventive effects of chebulic acid isolated from Terminalia chebula on advanced glycation endproduct-induced endothelial cell dysfunction[J]. Journal of Ethnopharmacology, 2010, 131(3): 567-574. [Content Brief]

[4]. Lee H S, et al. Isolation of chebulic acid from Terminalia chebula Retz. and its antioxidant effect in isolated rat hepatocytes[J]. Archives of Toxicology, 2007, 81: 211-218. [Content Brief]

[5]. Feng X H, et al. In vivo hepatoprotective activity and the underlying mechanism of chebulinic acid from Terminalia chebula fruit[J]. Phytomedicine, 2021, 83: 153479. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8071 mL	14.0355 mL	28.0710 mL	70.1774 mL
	5 mM	0.5614 mL	2.8071 mL	5.6142 mL	14.0355 mL
	10 mM	0.2807 mL	1.4035 mL	2.8071 mL	7.0177 mL
	15 mM	0.1871 mL	0.9357 mL	1.8714 mL	4.6785 mL
	20 mM	0.1404 mL	0.7018 mL	1.4035 mL	3.5089 mL
	25 mM	0.1123 mL	0.5614 mL	1.1228 mL	2.8071 mL
	30 mM	0.0936 mL	0.4678 mL	0.9357 mL	2.3392 mL
	40 mM	0.0702 mL	0.3509 mL	0.7018 mL	1.7544 mL
	50 mM	0.0561 mL	0.2807 mL	0.5614 mL	1.4035 mL
	60 mM	0.0468 mL	0.2339 mL	0.4678 mL	1.1696 mL
	80 mM	0.0351 mL	0.1754 mL	0.3509 mL	0.8772 mL
	100 mM	0.0281 mL	0.1404 mL	0.2807 mL	0.7018 mL

Keywords

Chebulic acid

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Chebulic acid

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Covalent Screening Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Pulmonary Fibrosis Compound Library

Radioprotector Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Chebulic acid

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Chebulic acid Related Classifications

HY-N4170 Related Classifications